Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VNDA 
Vanda Pharmaceuticals Inc (VNDA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/07/2025: VNDA (1-star) is a SELL. SELL since 4 days. Simulated Profits (-14.71%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $11.75
1 Year Target Price $11.75
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.47% | Avg. Invested days 24 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/07/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 260.03M USD | Price to earnings Ratio - | 1Y Target Price 11.75 |
Price to earnings Ratio - | 1Y Target Price 11.75 | ||
Volume (30-day avg) 3 | Beta 0.71 | 52 Weeks Range 3.81 - 5.70 | Updated Date 11/10/2025 |
52 Weeks Range 3.81 - 5.70 | Updated Date 11/10/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When Before Market | Estimate -0.45 | Actual -0.38 |
Profitability
Profit Margin -39.7% | Operating Margin (TTM) -55.61% |
Management Effectiveness
Return on Assets (TTM) -12.15% | Return on Equity (TTM) -16.72% |
Valuation
Trailing PE - | Forward PE 103.09 | Enterprise Value -9012090 | Price to Sales(TTM) 1.23 |
Enterprise Value -9012090 | Price to Sales(TTM) 1.23 | ||
Enterprise Value to Revenue 0.59 | Enterprise Value to EBITDA 12.91 | Shares Outstanding 59096630 | Shares Floating 49490473 |
Shares Outstanding 59096630 | Shares Floating 49490473 | ||
Percent Insiders 7.21 | Percent Institutions 78.19 |
Upturn AI SWOT
Vanda Pharmaceuticals Inc
Company Overview
History and Background
Vanda Pharmaceuticals Inc. was founded in 2002. It focuses on developing and commercializing innovative therapies to address unmet medical needs. Key milestones include the FDA approval of Hetlioz and Fanapt.
Core Business Areas
- Neurology: Focuses on treatments for sleep disorders, such as Hetlioz for Non-24-Hour Sleep-Wake Disorder.
- Gastroenterology: Focuses on treatments for gastrointestinal disorders, such as Tradipitant for gastroparesis.
- Psychiatry: Includes Fanapt, an atypical antipsychotic medication.
Leadership and Structure
Mihael H. Polymeropoulos is the President and CEO. The organizational structure includes departments for research and development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Hetlioz (tasimelteon): Hetlioz is used for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome. Competitors include melatonin supplements and off-label medications for sleep disorders. Revenue data is part of total product revenues. Precise market share is difficult to ascertain.
- Fanapt (iloperidone): Fanapt is an atypical antipsychotic medication for schizophrenia. Competitors include other atypical antipsychotics like risperidone, quetiapine, and olanzapine. Revenue data is part of total product revenues. Precise market share data is not readily available.
- Tradipitant: Tradipitant is in development for gastroparesis. There are currently no direct competitors as the product is not yet approved.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive and regulated. It involves research, development, manufacturing, and marketing of drugs.
Positioning
Vanda Pharmaceuticals Inc. is a specialty pharmaceutical company focused on niche markets with unmet needs. Its competitive advantage lies in its focus on specific disorders.
Total Addressable Market (TAM)
The TAM for Vanda's products varies. Sleep disorder treatments and antipsychotics represent multi-billion dollar markets. Vanda focuses on specific segments within these markets.
Upturn SWOT Analysis
Strengths
- Specialized Focus
- FDA-Approved Products
- Innovative Therapies in Development
Weaknesses
- Limited Product Portfolio
- Reliance on Key Products
- History of net losses
Opportunities
- Expanding into New Markets
- Developing New Therapies
- Partnerships and Collaborations
Threats
- Competition from Larger Pharmaceutical Companies
- Regulatory Changes
- Patent Expiry
Competitors and Market Share
Key Competitors
- LLY
- TEVA
- ABBV
Competitive Landscape
Vanda's competitive advantage lies in niche markets and specialized products. It faces strong competition from larger, diversified pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by sales of Hetlioz and Fanapt. However, growth rates have fluctuated.
Future Projections: Future growth is projected based on potential approvals of new therapies and market expansion. These projections vary widely based on source and assumptions.
Recent Initiatives: Recent initiatives include clinical trials for Tradipitant and efforts to expand market reach for existing products.
Summary
Vanda Pharmaceuticals is a specialty pharma company with niche offerings, but it faces revenue stability and strong competition. Its success hinges on its development of Tradipitant and its ability to commercialize it effectively. The company also needs to diversify its product portfolio and navigate regulatory challenges. Vanda has limited resources compared to larger pharma companies and is exposed to patent expiry risk.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Vanda Pharmaceuticals Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market data is dynamic and subject to change. All investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vanda Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Washington, DC, United States | ||
IPO Launch date 2006-04-12 | Founder, President, CEO & Chairman of The Board Dr. Mihael H. Polymeropoulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 368 | Website https://www.vandapharma.com |
Full time employees 368 | Website https://www.vandapharma.com | ||
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company's pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.